Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10313285" target="_blank" >RIV/00216208:11110/15:10313285 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/15:00086442 RIV/00216208:11120/15:43909659 RIV/65269705:_____/15:00063934 RIV/00064173:_____/15:#0000477 RIV/00064165:_____/15:10313285
Result on the web
<a href="http://dx.doi.org/10.3324/haematol.2014.121459" target="_blank" >http://dx.doi.org/10.3324/haematol.2014.121459</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3324/haematol.2014.121459" target="_blank" >10.3324/haematol.2014.121459</a>

Result language
angličtina
Original language name
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study
Original language description
While fludarabine-based regimens are a standard for treatment of chronic lymphocytic leukemia (CLL), patients who become refractory to fludarabine have had low response rates with salvage therapy and poor survival outcomes. We reported that ofatumumab, ahuman monoclonal antibody that binds to a distinct epitope of the CD20 molecule on B cells, was effective as monotherapy for fludarabine-refractory CLL at the interim analysis. Here we report the final analysis of the study, including a landmark analysis demonstrating clinical benefit in patients who responded and the results of pharmacokinetic analyses and of exploratory analyses to identify factors associated with ofatumumab pharmacokinetics and clinical outcomes.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)